4 January 2016 - The IQWiG examined whether pomalidomide offers an added benefit over the appropriate comparator therapy. No such added benefit could be derived, however, because the dossier contained no suitable data.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/pomalidomide-in-multiple-myeloma-no-hints-of-added-benefit.7123.html